| ￥2800 | |
| Z05032-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 77.16 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 85-100 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of APLP2, His, Human is greater than 95% as determined by SEC-HPLC. »
APLP2, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Amyloid β precursor-like protein 2 (APLP2) has been determined to serve an important role in the progression of a number of cancer types. APLP2 expression was significantly associated with disease-specific survival (P<0.001). APLP2 may be used to potentially predict patient prognosis, and to guide clinical diagnosis and treatment in CCRCC. |
| Synonyms | APPH; CDEBP; CDEI box-binding; APPL2; YWK-II; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
